Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?
- 31 March 2002
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 3 (3), 145-153
- https://doi.org/10.1016/s1470-2045(02)00677-0
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Symptom reporting in cancer patients IICancer, 1999
- Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancerBritish Journal of Cancer, 1999
- Patients' attitudes regarding out-of-hospital blood transfusionTransfusion, 1996
- Nonspecific effects in longitudinal studies: Impact on quality of life measuresJournal of Clinical Epidemiology, 1996
- Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapyCancer, 1995
- Does recombinant human erythropoietin not only treat anemia but reduce postpartum (emotional) distress as well?jpme, 1995
- Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatinEuropean Journal Of Cancer, 1993
- Erythropoietin for anaemia in cancer patientsEuropean Journal Of Cancer, 1993
- Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnosesQuality of Life Research, 1993
- EVALUATION OF QUALITY OF LIFE IN PATIENTS RECEIVING TREATMENT FOR ADVANCED BREAST CANCERThe Lancet, 1976